Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
BioCryst announces acceptance, accelerated review of ORLADEYO in Israel » 07:05
06/16/21
06/16
07:05
06/16/21
07:05
BCRX

BioCryst

$15.60 /

-0.665 (-4.09%)

BioCryst Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BCRX BioCryst
$15.60 /

-0.665 (-4.09%)

BCRX BioCryst
$15.60 /

-0.665 (-4.09%)

05/28/21 Piper Sandler
BioCryst price target raised to $18 from $15 at Piper Sandler
05/07/21 Barclays
BioCryst price target raised to $20 from $13 at Barclays
05/06/21 Evercore ISI
BioCryst price target raised to $20 from $16 at Evercore ISI
04/30/21 JMP Securities
JMP Securities reiterates Outperform on BioCryst after Orladeyo's EU approval
BCRX BioCryst
$15.60 /

-0.665 (-4.09%)

BCRX BioCryst
$15.60 /

-0.665 (-4.09%)

BCRX BioCryst
$15.60 /

-0.665 (-4.09%)

BCRX BioCryst
$15.60 /

-0.665 (-4.09%)

Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/16/21
06/16
04:55
06/16/21
04:55
APTO

Aptose Biosciences

$3.50 /

-0.21 (-5.66%)

, MBIO

Mustang Bio

$3.57 /

-0.115 (-3.13%)

, QURE

uniQure

$34.46 /

-0.43 (-1.23%)

, RIGL

Rigel Pharmaceuticals

$4.27 /

-0.1 (-2.29%)

, MGTA

Magenta Therapeutics

$11.38 /

+0.05 (+0.44%)

, MEIP

MEI Pharma

$3.10 /

-0.15 (-4.62%)

, CRIS

Curis

$7.61 /

-0.44 (-5.47%)

, XLRN

Acceleron

$128.63 /

-2.39 (-1.82%)

, EPZM

Epizyme

$8.79 /

-0.025 (-0.28%)

, INCY

Incyte

$82.69 /

+0.11 (+0.13%)

, ORTX

Orchard Therapeutics

$4.85 /

-0.19 (-3.77%)

, TGTX

TG Therapeutics

$37.42 /

-0.88 (-2.30%)

, EQ

Equillium

$6.05 /

+0.05 (+0.83%)

, JAZZ

Jazz Pharmaceuticals

$183.42 /

-2.7 (-1.45%)

, VRTX

Vertex Pharmaceuticals

$188.94 /

-5.87 (-3.01%)

, SGEN

Seagen

$153.20 /

-2.99 (-1.91%)

, IMRA

Imara

$8.26 /

-0.44 (-5.06%)

, GBT

Global Blood Therapeutics

$39.60 /

-0.65 (-1.61%)

, BGNE

BeiGene

$332.97 /

-9.75 (-2.84%)

, APLS

Apellis

$60.63 /

-4.27 (-6.58%)

, AGIO

Agios Pharmaceuticals

$58.23 /

+0.04 (+0.07%)

, FMTX

Forma Therapeutics

$24.13 /

-0.09 (-0.37%)

, KROS

Keros Therapeutics

$52.55 /

-0.455 (-0.86%)

, CYAD

Celyad

$5.44 /

+0.03 (+0.55%)

, ALXN

Alexion

$181.90 /

+0.25 (+0.14%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

CYAD Celyad
$5.44 /

+0.03 (+0.55%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$34.46 /

-0.43 (-1.23%)

06/14/21 BTIG
uniQure initiated with a Buy at BTIG
05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

06/14/21 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$7.61 /

-0.44 (-5.47%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$82.69 /

+0.11 (+0.13%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$6.05 /

+0.05 (+0.83%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

06/14/21 Truist
Vertex Pharmaceuticals price target raised to $331 from $305 at Truist
06/14/21 SVB Leerink
Vertex Pharmaceuticals price target lowered to $200 from $250 at SVB Leerink
06/14/21 Deutsche Bank
Grifols upgraded to Buy from Hold at Deutsche Bank
06/13/21 Piper Sandler
Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
SGEN Seagen
$153.20 /

-2.99 (-1.91%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$8.26 /

-0.44 (-5.06%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
APLS Apellis
$60.63 /

-4.27 (-6.58%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.44 /

+0.03 (+0.55%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$181.90 /

+0.25 (+0.14%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$128.63 /

-2.39 (-1.82%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

MGTA Magenta Therapeutics
$11.38 /

+0.05 (+0.44%)

MEIP MEI Pharma
$3.10 /

-0.15 (-4.62%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

KROS Keros Therapeutics
$52.55 /

-0.455 (-0.86%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

BGNE BeiGene
$332.97 /

-9.75 (-2.84%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

AGIO Agios Pharmaceuticals
$58.23 /

+0.04 (+0.07%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

RIGL Rigel Pharmaceuticals
$4.27 /

-0.1 (-2.29%)

ORTX Orchard Therapeutics
$4.85 /

-0.19 (-3.77%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

EPZM Epizyme
$8.79 /

-0.025 (-0.28%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

TGTX TG Therapeutics
$37.42 /

-0.88 (-2.30%)

SGEN Seagen
$153.20 /

-2.99 (-1.91%)

QURE uniQure
$34.46 /

-0.43 (-1.23%)

MBIO Mustang Bio
$3.57 /

-0.115 (-3.13%)

JAZZ Jazz Pharmaceuticals
$183.42 /

-2.7 (-1.45%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

IMRA Imara
$8.26 /

-0.44 (-5.06%)

GBT Global Blood Therapeutics
$39.60 /

-0.65 (-1.61%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

APTO Aptose Biosciences
$3.50 /

-0.21 (-5.66%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

VRTX Vertex Pharmaceuticals
$188.94 /

-5.87 (-3.01%)

INCY Incyte
$82.69 /

+0.11 (+0.13%)

FMTX Forma Therapeutics
$24.13 /

-0.09 (-0.37%)

EQ Equillium
$6.05 /

+0.05 (+0.83%)

CRIS Curis
$7.61 /

-0.44 (-5.47%)

APLS Apellis
$60.63 /

-4.27 (-6.58%)

ALXN Alexion
$181.90 /

+0.25 (+0.14%)

Yesterday
Recommendations
Jounce Therapeutics receives $25M milestone from Gilead, says Piper Sandler » 12:22
06/15/21
06/15
12:22
06/15/21
12:22
JNCE

Jounce Therapeutics

$7.84 /

+0.87 (+12.48%)

, GILD

Gilead

$67.89 /

-0.26 (-0.38%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating and $20 price target on Jounce Therapeutics (JNCE), which will receive a $25M milestone from partner Gilead (GILD) for IND clearance for anti-CCR8 antibody GS-1811. Jounce, which expects to initiate eight expansion cohorts in 2H21, now holds pro forma cash of roughly $296M to advance its innovative I-O pipeline, Tenthoff tells investors in a research note.

ShowHide Related Items >><<
JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
GILD Gilead
$67.89 /

-0.26 (-0.38%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

  • 10
    Mar
GILD Gilead
$67.89 /

-0.26 (-0.38%)

JNCE Jounce Therapeutics
$7.84 /

+0.87 (+12.48%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

GILD Gilead
$67.89 /

-0.26 (-0.38%)

Options
BioCryst call volume above normal and directionally bullish » 12:05
06/15/21
06/15
12:05
06/15/21
12:05
BCRX

BioCryst

$15.62 /

-0.645 (-3.97%)

Bullish option flow…

Bullish option flow detected in BioCryst with 7,808 calls trading, 1.1x expected, and implied vol increasing over 2 points to 76.37%. Sep-21 20 calls and Jun-21 16 puts are the most active options, with total volume in those strikes near 2,900 contracts. The Put/Call Ratio is 0.28. Earnings are expected on August 5th.

ShowHide Related Items >><<
BCRX BioCryst
$15.62 /

-0.645 (-3.97%)

BCRX BioCryst
$15.62 /

-0.645 (-3.97%)

05/28/21 Piper Sandler
BioCryst price target raised to $18 from $15 at Piper Sandler
05/07/21 Barclays
BioCryst price target raised to $20 from $13 at Barclays
05/06/21 Evercore ISI
BioCryst price target raised to $20 from $16 at Evercore ISI
04/30/21 JMP Securities
JMP Securities reiterates Outperform on BioCryst after Orladeyo's EU approval
BCRX BioCryst
$15.62 /

-0.645 (-3.97%)

BCRX BioCryst
$15.62 /

-0.645 (-3.97%)

BCRX BioCryst
$15.62 /

-0.645 (-3.97%)

BCRX BioCryst
$15.62 /

-0.645 (-3.97%)

Initiation
Fly Intel: Top five analyst initiations » 09:54
06/15/21
06/15
09:54
06/15/21
09:54
ACRS

Aclaris Therapeutics

$17.90 /

+0.17 (+0.96%)

, OTLY

Oatly Group

$27.30 /

-0.0901 (-0.33%)

, MYGN

Myriad Genetics

$30.05 /

+0.12 (+0.40%)

, EXEL

Exelixis

$23.00 /

+0.24 (+1.05%)

, GH

Guardant Health

$122.27 /

-1.41 (-1.14%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aclaris Therapeutics (ACRS) initiated with an Overweight at Piper Sandler. 2. Oatly Group (OTLY) initiated with a Hold at Nordea. 3. Myriad Genetics (MYGN) initiated with a Market Perform at Raymond James. 4. Exelixis (EXEL) initiated with a Buy at H.C. Wainwright. 5. Guardant Health (GH) initiated with a Market Perform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
MYGN Myriad Genetics
$30.05 /

+0.12 (+0.40%)

GH Guardant Health
$122.27 /

-1.41 (-1.14%)

EXEL Exelixis
$23.00 /

+0.24 (+1.05%)

ACRS Aclaris Therapeutics
$17.90 /

+0.17 (+0.96%)

ACRS Aclaris Therapeutics
$17.90 /

+0.17 (+0.96%)

06/15/21 Piper Sandler
Aclaris Therapeutics initiated with an Overweight at Piper Sandler
04/21/21 H.C. Wainwright
Aclaris Therapeutics initiated with a Buy at H.C. Wainwright
03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
OTLY Oatly Group
$27.30 /

-0.0901 (-0.33%)

06/15/21 Nordea
Oatly Group initiated with a Hold at Nordea
06/14/21
Fly Intel: Top five analyst initiations
06/14/21 Jefferies
Oatly Group initiated with a Buy at Jefferies
06/14/21 JPMorgan
Oatly Group initiated with a Neutral at JPMorgan
MYGN Myriad Genetics
$30.05 /

+0.12 (+0.40%)

06/15/21 Raymond James
Myriad Genetics initiated with a Market Perform at Raymond James
06/03/21 Goldman Sachs
Myriad Genetics initiated with a Sell at Goldman Sachs
05/03/21 William Blair
LabCorp's Vectra deal likely not the last for this year, says William Blair
02/24/21 SVB Leerink
Myriad Genetics price target raised to $33 from $20 at SVB Leerink
EXEL Exelixis
$23.00 /

+0.24 (+1.05%)

06/15/21 H.C. Wainwright
Exelixis initiated with a Buy at H.C. Wainwright
05/25/21 Stifel
Exelixis' COSMIC-021 cohort 6 results 'incrementally negative,' says Stifel
05/18/21 Goldman Sachs
Exelixis assumed with a Sell at Goldman Sachs
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
GH Guardant Health
$122.27 /

-1.41 (-1.14%)

06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
06/03/21
Fly Intel: Top five analyst initiations
06/03/21 Goldman Sachs
Guardant Health initiated with a Buy at Goldman Sachs
05/25/21 Wells Fargo
Guardant Health initiated with an Overweight at Wells Fargo
MYGN Myriad Genetics
$30.05 /

+0.12 (+0.40%)

GH Guardant Health
$122.27 /

-1.41 (-1.14%)

EXEL Exelixis
$23.00 /

+0.24 (+1.05%)

ACRS Aclaris Therapeutics
$17.90 /

+0.17 (+0.96%)

  • 10
    Jun
  • 20
    May
  • 20
    Jan
  • 07
    Oct
OTLY Oatly Group
$27.30 /

-0.0901 (-0.33%)

OTLY Oatly Group
$27.30 /

-0.0901 (-0.33%)

MYGN Myriad Genetics
$30.05 /

+0.12 (+0.40%)

GH Guardant Health
$122.27 /

-1.41 (-1.14%)

EXEL Exelixis
$23.00 /

+0.24 (+1.05%)

ACRS Aclaris Therapeutics
$17.90 /

+0.17 (+0.96%)

OTLY Oatly Group
$27.30 /

-0.0901 (-0.33%)

MYGN Myriad Genetics
$30.05 /

+0.12 (+0.40%)

Hot Stocks
Jounce Therapeutics achieves first milestone in license agreement with Gilead » 08:04
06/15/21
06/15
08:04
06/15/21
08:04
JNCE

Jounce Therapeutics

$6.98 /

-0.07 (-0.99%)

, GILD

Gilead

$68.15 /

+0.09 (+0.13%)

Jounce Therapeutics…

Jounce Therapeutics (JNCE) announced the Food and Drug Administration's clearance of its Investigational New Drug application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences (GILD) has exclusive rights to develop and commercialize. The IND clearance triggers a $25M milestone payment to Jounce. Under the terms of the September 2020 agreement, Gilead invested $35M in Jounce's common stock and made an $85M upfront payment to Jounce. Jounce has led the development of JTX-1811 through IND clearance, after which Gilead now has the sole right to develop and commercialize the program. After receiving this $25M milestone payment, Jounce may receive up to an additional $660M in future clinical, regulatory and commercial milestone payments and will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales. Any milestone or royalty paid to Jounce is subject to certain reductions as described in the license agreement.

ShowHide Related Items >><<
JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

04/12/21 Roth Capital
Jounce reported 'very robust' JTX-8064 analysis, says Roth Capital
03/14/21 Piper Sandler
Jounce Therapeutics initiated with an Overweight at Piper Sandler
02/26/21 H.C. Wainwright
Jounce Therapeutics price target raised to $15 from $11 at H.C. Wainwright
12/04/20 H.C. Wainwright
Jounce Therapeutics assumed with a Buy at H.C. Wainwright
GILD Gilead
$68.15 /

+0.09 (+0.13%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

  • 10
    Mar
GILD Gilead
$68.15 /

+0.09 (+0.13%)

JNCE Jounce Therapeutics
$6.98 /

-0.07 (-0.99%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

GILD Gilead
$68.15 /

+0.09 (+0.13%)

Initiation
ADC Therapeutics initiated with an Overweight at Cantor Fitzgerald » 06:58
06/15/21
06/15
06:58
06/15/21
06:58
ADCT

ADC Therapeutics

$23.17 /

+1.015 (+4.58%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Brian Cheng initiated coverage of ADC Therapeutics with an Overweight rating and $46 price target. Cheng believes the current share price represents an attractive entry point based on strong underlying fundamentals and thinks the company's extensive pipeline portfolio is largely underappreciated as the floor of its valuation is well-supported by the growing revenue stream from Zynlonta sales, the analyst tells investors in a research note.

ShowHide Related Items >><<
ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

06/15/21 Cantor Fitzgerald
ADC Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

  • 24
    Sep
Initiation
ADC Therapeutics initiated with an Overweight at Cantor Fitzgerald » 06:53
06/15/21
06/15
06:53
06/15/21
06:53
ADCT

ADC Therapeutics

$23.17 /

+1.015 (+4.58%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Brian Cheng initiated coverage of ADC Therapeutics with an Overweight rating and $46 price target.

ShowHide Related Items >><<
ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

05/14/21 H.C. Wainwright
ADC Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
12/02/20 Stifel
ADC Therapeutics initiated with a Hold at Stifel
ADCT ADC Therapeutics
$23.17 /

+1.015 (+4.58%)

  • 24
    Sep
Initiation
Exelixis initiated with a Buy at H.C. Wainwright » 06:05
06/15/21
06/15
06:05
06/15/21
06:05
EXEL

Exelixis

$22.76 /

-0.24 (-1.04%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Michael King initiated coverage of Exelixis with a Buy rating and $47 price target. The company is a market leader in various solid tumors, led by the rapidly evolving fields of renal cell carcinoma and hepatocellular carcinoma, King tells investors in a research note. The analyst says Exelixis promises to expand its cabozantinib franchise by garnering further label expansions.

ShowHide Related Items >><<
EXEL Exelixis
$22.76 /

-0.24 (-1.04%)

EXEL Exelixis
$22.76 /

-0.24 (-1.04%)

05/25/21 Stifel
Exelixis' COSMIC-021 cohort 6 results 'incrementally negative,' says Stifel
05/18/21 Goldman Sachs
Exelixis assumed with a Sell at Goldman Sachs
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
EXEL Exelixis
$22.76 /

-0.24 (-1.04%)

EXEL Exelixis
$22.76 /

-0.24 (-1.04%)

Conference/Events
European Hematology Association to hold virtual meeting » 04:55
06/15/21
06/15
04:55
06/15/21
04:55
APTO

Aptose Biosciences

$3.71 /

-0.04 (-1.07%)

, MBIO

Mustang Bio

$3.68 /

-0.11 (-2.90%)

, QURE

uniQure

$34.89 /

-1.24 (-3.43%)

, RIGL

Rigel Pharmaceuticals

$4.37 /

+0.35 (+8.71%)

, MGTA

Magenta Therapeutics

$11.33 /

-0.22 (-1.90%)

, MEIP

MEI Pharma

$3.28 /

+0.005 (+0.15%)

, CRIS

Curis

$8.05 /

+0.05 (+0.63%)

, XLRN

Acceleron

$131.02 /

-2.4 (-1.80%)

, EPZM

Epizyme

$8.81 /

+0.305 (+3.59%)

, INCY

Incyte

$82.61 /

+0.03 (+0.04%)

, ORTX

Orchard Therapeutics

$5.04 /

-0.09 (-1.75%)

, TGTX

TG Therapeutics

$38.30 /

+0.49 (+1.30%)

, EQ

Equillium

$6.00 /

-0.12 (-1.96%)

, JAZZ

Jazz Pharmaceuticals

$186.45 /

+0.15 (+0.08%)

, VRTX

Vertex Pharmaceuticals

$194.81 /

+1.78 (+0.92%)

, SGEN

Seagen

$156.25 /

-0.21 (-0.13%)

, IMRA

Imara

$8.70 /

+0.135 (+1.58%)

, GBT

Global Blood Therapeutics

$40.25 /

-0.32 (-0.79%)

, BGNE

BeiGene

$344.52 /

-5.39 (-1.54%)

, APLS

Apellis

$64.90 /

+2.8 (+4.51%)

, AGIO

Agios Pharmaceuticals

$58.20 /

+0.43 (+0.74%)

, FMTX

Forma Therapeutics

$24.22 /

+1.41 (+6.18%)

, KROS

Keros Therapeutics

$53.00 /

+1.64 (+3.19%)

, CYAD

Celyad

$5.41 /

-0.29 (-5.09%)

, ALXN

Alexion

$181.65 /

+0.08 (+0.04%)

EHA 2021 Virtual Congress…

EHA 2021 Virtual Congress to be held on June 9-17. Webcast Link

ShowHide Related Items >><<
XLRN Acceleron
$131.02 /

-2.4 (-1.80%)

VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

TGTX TG Therapeutics
$38.30 /

+0.49 (+1.30%)

SGEN Seagen
$156.25 /

-0.21 (-0.13%)

RIGL Rigel Pharmaceuticals
$4.37 /

+0.35 (+8.71%)

QURE uniQure
$34.89 /

-1.24 (-3.43%)

ORTX Orchard Therapeutics
$5.04 /

-0.09 (-1.75%)

MGTA Magenta Therapeutics
$11.33 /

-0.22 (-1.90%)

MEIP MEI Pharma
$3.28 /

+0.005 (+0.15%)

MBIO Mustang Bio
$3.68 /

-0.11 (-2.90%)

KROS Keros Therapeutics
$53.00 /

+1.64 (+3.19%)

JAZZ Jazz Pharmaceuticals
$186.45 /

+0.15 (+0.08%)

INCY Incyte
$82.61 /

+0.03 (+0.04%)

IMRA Imara
$8.70 /

+0.135 (+1.58%)

GBT Global Blood Therapeutics
$40.25 /

-0.32 (-0.79%)

FMTX Forma Therapeutics
$24.22 /

+1.41 (+6.18%)

EQ Equillium
$6.00 /

-0.12 (-1.96%)

EPZM Epizyme
$8.81 /

+0.305 (+3.59%)

CYAD Celyad
$5.41 /

-0.29 (-5.09%)

CRIS Curis
$8.05 /

+0.05 (+0.63%)

BGNE BeiGene
$344.52 /

-5.39 (-1.54%)

APTO Aptose Biosciences
$3.71 /

-0.04 (-1.07%)

APLS Apellis
$64.90 /

+2.8 (+4.51%)

ALXN Alexion
$181.65 /

+0.08 (+0.04%)

AGIO Agios Pharmaceuticals
$58.20 /

+0.43 (+0.74%)

APTO Aptose Biosciences
$3.71 /

-0.04 (-1.07%)

02/22/21 JonesTrading
Aptose Biosciences resumed with a Buy at JonesTrading
10/19/20 Cantor Fitzgerald
Aptose Biosciences initiated with an Overweight at Cantor Fitzgerald
09/22/20 Alliance Global Partners
Aptose Biosciences initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
MBIO Mustang Bio
$3.68 /

-0.11 (-2.90%)

05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/17/21 BTIG
Mustang Bio initiated with a Buy at BTIG
05/12/21 Cantor Fitzgerald
Mustang Bio EHA abstract data 'looks promising,' says Cantor Fitzgerald
12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
QURE uniQure
$34.89 /

-1.24 (-3.43%)

06/14/21 BTIG
uniQure initiated with a Buy at BTIG
05/20/21 UBS
uniQure initiated with a Neutral at UBS
05/19/21 H.C. Wainwright
uniQure price target raised to $90 from $80 at H.C. Wainwright
04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
RIGL Rigel Pharmaceuticals
$4.37 /

+0.35 (+8.71%)

06/11/21 BMO Capital
Rigel Pharmaceuticals coverage transferred at BMO Capital
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
04/13/21 Piper Sandler
Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
MGTA Magenta Therapeutics
$11.33 /

-0.22 (-1.90%)

06/14/21 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
05/18/21 B. Riley
Magenta Therapeutics initiated with a Buy, $21 target at B. Riley
05/17/21 B. Riley
Magenta Therapeutics initiated with a Buy at B. Riley
05/13/21 Mizuho
Magenta Therapeutics price target raised to $17 from $16 at Mizuho
MEIP MEI Pharma
$3.28 /

+0.005 (+0.15%)

04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
CRIS Curis
$8.05 /

+0.05 (+0.63%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
XLRN Acceleron
$131.02 /

-2.4 (-1.80%)

06/11/21 H.C. Wainwright
Acceleron results for Phase 2 BEYOND study 'impressive,' says H.C. Wainwright
05/19/21 Piper Sandler
Piper remains bullish on Acceleron after Phase 2 PULSAR OLE, SPECTRA updates
04/26/21 Credit Suisse
Acceleron assumed with an Outperform at Credit Suisse
03/23/21
Fly Intel: Top five analyst downgrades
EPZM Epizyme
$8.81 /

+0.305 (+3.59%)

05/07/21 SVB Leerink
Epizyme upgraded to Outperform from Market Perform at SVB Leerink
04/23/21 Cowen
Epizyme transferred with Outperform at Cowen
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Epizyme initiated with an Outperform at Credit Suisse
INCY Incyte
$82.61 /

+0.03 (+0.04%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ORTX Orchard Therapeutics
$5.04 /

-0.09 (-1.75%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
TGTX TG Therapeutics
$38.30 /

+0.49 (+1.30%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
EQ Equillium
$6.00 /

-0.12 (-1.96%)

03/03/21
Fly Intel: Top five analyst initiations
03/03/21 JonesTrading
Equillium initiated with a Buy at JonesTrading
11/30/20 H.C. Wainwright
Equillium price target lowered to $12 from $22 at H.C. Wainwright
07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
JAZZ Jazz Pharmaceuticals
$186.45 /

+0.15 (+0.08%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

06/14/21 Truist
Vertex Pharmaceuticals price target raised to $331 from $305 at Truist
06/14/21 SVB Leerink
Vertex Pharmaceuticals price target lowered to $200 from $250 at SVB Leerink
06/14/21 Deutsche Bank
Grifols upgraded to Buy from Hold at Deutsche Bank
06/13/21 Piper Sandler
Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler
SGEN Seagen
$156.25 /

-0.21 (-0.13%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
IMRA Imara
$8.70 /

+0.135 (+1.58%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
GBT Global Blood Therapeutics
$40.25 /

-0.32 (-0.79%)

05/07/21 Cantor Fitzgerald
Global Blood Therapeutics price target lowered to $110 from $120 at Cantor Fitzgerald
05/06/21 Piper Sandler
Global Blood price target lowered to $45 from $50 at Piper Sandler
04/14/21
Fly Intel: Top five analyst initiations
04/14/21 SVB Leerink
SVB Leerink bullish on Global Blood Therapeutics, initiates with an Outperform
BGNE BeiGene
$344.52 /

-5.39 (-1.54%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
APLS Apellis
$64.90 /

+2.8 (+4.51%)

05/20/21 UBS
Apellis initiated with a Buy at UBS
05/18/21 BMO Capital
Apellis price target raised to $68 from $64 at BMO Capital
05/17/21 Oppenheimer
Apellis price target raised to $67 from $64 at Oppenheimer
05/17/21 Raymond James
Apellis price target raised to $115 from $104 at Raymond James
AGIO Agios Pharmaceuticals
$58.20 /

+0.43 (+0.74%)

06/10/21 H.C. Wainwright
Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/30/21 Goldman Sachs
Agios Pharmaceuticals reinstated with a Neutral at Goldman Sachs
04/30/21 Barclays
Agios Pharmaceuticals price target raised to $70 from $65 at Barclays
03/30/21 Piper Sandler
Agios should rally on Forma Therapeutics data, says Piper Sandler
FMTX Forma Therapeutics
$24.22 /

+1.41 (+6.18%)

03/31/21 H.C. Wainwright
Forma Therapeutics price target raised to $55 from $53 at H.C. Wainwright
02/17/21
Fly Intel: Top five analyst initiations
02/17/21 Oppenheimer
Forma Therapeutics initiated with an Outperform at Oppenheimer
KROS Keros Therapeutics
$53.00 /

+1.64 (+3.19%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
CYAD Celyad
$5.41 /

-0.29 (-5.09%)

03/25/21 JonesTrading
Celyad downgraded to Hold from Buy at JonesTrading
12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
ALXN Alexion
$181.65 /

+0.08 (+0.04%)

05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
05/03/21 SVB Leerink
Alexion price target raised to $173 from $156 at SVB Leerink
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
XLRN Acceleron
$131.02 /

-2.4 (-1.80%)

VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

TGTX TG Therapeutics
$38.30 /

+0.49 (+1.30%)

SGEN Seagen
$156.25 /

-0.21 (-0.13%)

RIGL Rigel Pharmaceuticals
$4.37 /

+0.35 (+8.71%)

QURE uniQure
$34.89 /

-1.24 (-3.43%)

ORTX Orchard Therapeutics
$5.04 /

-0.09 (-1.75%)

MGTA Magenta Therapeutics
$11.33 /

-0.22 (-1.90%)

MEIP MEI Pharma
$3.28 /

+0.005 (+0.15%)

MBIO Mustang Bio
$3.68 /

-0.11 (-2.90%)

KROS Keros Therapeutics
$53.00 /

+1.64 (+3.19%)

JAZZ Jazz Pharmaceuticals
$186.45 /

+0.15 (+0.08%)

INCY Incyte
$82.61 /

+0.03 (+0.04%)

IMRA Imara
$8.70 /

+0.135 (+1.58%)

GBT Global Blood Therapeutics
$40.25 /

-0.32 (-0.79%)

FMTX Forma Therapeutics
$24.22 /

+1.41 (+6.18%)

EQ Equillium
$6.00 /

-0.12 (-1.96%)

EPZM Epizyme
$8.81 /

+0.305 (+3.59%)

CRIS Curis
$8.05 /

+0.05 (+0.63%)

BGNE BeiGene
$344.52 /

-5.39 (-1.54%)

APTO Aptose Biosciences
$3.71 /

-0.04 (-1.07%)

APLS Apellis
$64.90 /

+2.8 (+4.51%)

ALXN Alexion
$181.65 /

+0.08 (+0.04%)

AGIO Agios Pharmaceuticals
$58.20 /

+0.43 (+0.74%)

  • 15
    Dec
  • 09
    Dec
  • 11
    Dec
  • 02
    Dec
  • 13
    Nov
  • 14
    Aug
  • 16
    Jul
  • 01
    Jul
  • 25
    Jun
  • 19
    Jun
VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

RIGL Rigel Pharmaceuticals
$4.37 /

+0.35 (+8.71%)

ORTX Orchard Therapeutics
$5.04 /

-0.09 (-1.75%)

JAZZ Jazz Pharmaceuticals
$186.45 /

+0.15 (+0.08%)

INCY Incyte
$82.61 /

+0.03 (+0.04%)

EPZM Epizyme
$8.81 /

+0.305 (+3.59%)

VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

TGTX TG Therapeutics
$38.30 /

+0.49 (+1.30%)

SGEN Seagen
$156.25 /

-0.21 (-0.13%)

QURE uniQure
$34.89 /

-1.24 (-3.43%)

MBIO Mustang Bio
$3.68 /

-0.11 (-2.90%)

JAZZ Jazz Pharmaceuticals
$186.45 /

+0.15 (+0.08%)

INCY Incyte
$82.61 /

+0.03 (+0.04%)

IMRA Imara
$8.70 /

+0.135 (+1.58%)

GBT Global Blood Therapeutics
$40.25 /

-0.32 (-0.79%)

EQ Equillium
$6.00 /

-0.12 (-1.96%)

CRIS Curis
$8.05 /

+0.05 (+0.63%)

APTO Aptose Biosciences
$3.71 /

-0.04 (-1.07%)

APLS Apellis
$64.90 /

+2.8 (+4.51%)

ALXN Alexion
$181.65 /

+0.08 (+0.04%)

VRTX Vertex Pharmaceuticals
$194.81 /

+1.78 (+0.92%)

INCY Incyte
$82.61 /

+0.03 (+0.04%)

FMTX Forma Therapeutics
$24.22 /

+1.41 (+6.18%)

EQ Equillium
$6.00 /

-0.12 (-1.96%)

CRIS Curis
$8.05 /

+0.05 (+0.63%)

APLS Apellis
$64.90 /

+2.8 (+4.51%)

ALXN Alexion
$181.65 /

+0.08 (+0.04%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.